EN HU
logo Tudóstér

Vereb György

Vereb György

Publication list

Tudóstér co-authors statistics filterable publication list
Uploaded publications:
153
Publications in DEA:
144
OA:
48
Date range:
1990-2025
2025
1.
Nagy, L., Nagy, G., Juhász, T., Fillér, C., Szűcs, G., Szekanecz, Z., Vereb, G., Antal-Szalmás, P., Szöőr, Á.: Comparative Evaluation of Bleomycin- and Collagen-V-Induced Models of Systemic Sclerosis: insights into Fibrosis and Autoimmunity for Translational Research.
Int. J. Mol. Sci. 26 (6), 1-15, (article identifier: 2618), 2025.
doi DEA
Journal metrics:
Q2 Catalysis (2024)
Q1 Computer Science Applications (2024)
Q1 Inorganic Chemistry (2024)
Q1 Medicine (miscellaneous) (2024)
Q2 Molecular Biology (2024)
D1 Organic Chemistry (2024)
Q1 Physical and Theoretical Chemistry (2024)
D1 Spectroscopy (2024)
2.
Kemenes, G., Rebenku, I., Bajdik, B., Vereb, G., Takács, L.: Correlation of Multimodal Clinical Imaging With the Whole-Slide- and Superresolution-Based Immunohistological Structure of the Corneal Limbal Stroma.
Invest. Ophthalmol. Vis. Sci. 66 (9), 1-13, (article identifier: 54), 2025.
doi DEA WoS Scopus
Journal metrics:
Q2 Cellular and Molecular Neuroscience (2024)
Q1 Ophthalmology (2024)
Q1 Sensory Systems (2024)
3.
Kemenes, G., Rebenku, I., Vereb, G., Takács, L.: Developing an ex vivo human cornea model for discovering the cellular interactions in simple limbal epithelial transplantation.
Invest. Ophthalmol. Vis. Sci. 66 (8), 1042, 2025.
DEA
4.
Pourjamal, N., Le Joncour, V., Vereb, G., Honkamaki, C., Isola, J., Leyton, J. V., Laakkonen, P., Joensuu, H., Barok, M.: Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan.
Translational Oncology. 53, 1-9, (article identifier: 102284), 2025.
doi DEA WoS Scopus
Journal metrics:
Q2 Cancer Research (2024)
Q1 Oncology (2024)
5.
Ujlaky-Nagy, L., Szöllősi, J., Vereb, G.: EGFR-HER2 Transactivation Viewed in Space and Time Through the Versatile Spectacles of Imaging Cytometry - Implications for Targeted Therapy.
Cytom. Part A. 107 (3), 187-202, 2025.
doi DEA WoS Scopus
Journal metrics:
Q3 Cell Biology (2024)
Q1 Histology (2024)
Q1 Pathology and Forensic Medicine (2024)
6.
Horváth, D., Pénzes, Z., Molnár, P., Rebenku, I., Vereb, G., Szántó, M., Muzsai, S., Szegedi, A., Dajnoki, Z., Pázmándi, K. L., Fekete, T., Bácsi, A., Szöllősi, A. G.: Natriuretic peptides modulate monocyte-derived Langerhans cell differentiation and promote a migratory phenotype.
Front. Immunol. 16, 1-14, (article identifier: 1593141), 2025.
doi DEA WoS Scopus
Journal metrics:
Q1 Immunology (2024)
Q1 Immunology and Allergy (2024)
7.
Gergely, B., Vereb, M. A., Rebenku, I., Vereb, G., Szöőr, Á.: Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy.
Cancers. 17 (5), 1-17, (article identifier: 731), 2025.
doi DEA WoS Scopus
Journal metrics:
Q2 Cancer Research (2024)
Q1 Oncology (2024)
2024
8.
Ujlaky-Nagy, L., Szöllősi, J., Vereb, G.: Disrupting EGFR-HER2 Transactivation by Pertuzumab in HER2-Positive Cancer: quantitative Analysis Reveals EGFR Signal Input as Potential Predictor of Therapeutic Outcome.
Int. J. Mol. Sci. 25 (11), 1-20, (article identifier: 5978), 2024.
doi DEA Scopus
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
Q1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
D1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
9.
Medyouni, G., Vörös, O., Jusztus, V., Panyi, G., Vereb, G., Szöőr, Á., Hajdu, P.: Inhibition of K+ Channels Affects the Target Cell Killing Potential of CAR T Cells.
Cancers (Basel). 16 (22), 1-12, (article identifier: 3750), 2024.
doi DEA WoS Scopus
Journal metrics:
Q2 Cancer Research
Q1 Oncology
10.
Barden, M., Elsenbroich, P. R., Haas, V., Ertelt, M., Pervan, P., Velas, L., Gergely, B., Szöőr, Á., Harrer, D. C., Bezler, V., Holzinger, A., Friis, R. U. W., Vereb, G., Schütz, G., Schoeder, C. T., Hombach, A. A., Abken, H.: Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function.
J. Immunother. Cancer. 12 (12), 1-14, (article identifier: 010208), 2024.
doi DEA WoS Scopus
Journal metrics:
D1 Cancer Research
D1 Immunology
D1 Immunology and Allergy
D1 Molecular Medicine
D1 Oncology
D1 Pharmacology
11.
Nagy, L., Mezősi-Csaplár, M., Rebenku, I., Vereb, G., Szöőr, Á.: Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC.
Front. Immunol. 15, 1-38, (article identifier: 1365172), 2024.
doi DEA WoS Scopus
Journal metrics:
Q1 Immunology
Q1 Immunology and Allergy
2023
12.
Barden, M., Holzinger, A., Velas, L., Mezősi-Csaplár, M., Szöőr, Á., Vereb, G., Schütz, G., Hombach, A. A., Abken, H.: CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation.
Front. Immunol. 14, 1-13, (article identifier: 1110482), 2023.
doi DEA WoS Scopus
Journal metrics:
Q1 Immunology
Q1 Immunology and Allergy
13.
Mezősi-Csaplár, M., Szöőr, Á., Vereb, G.: CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells.
Cancers (Basel). 15 (12), 3081-3097, (article identifier: 3081), 2023.
doi DEA WoS Scopus
Journal metrics:
Q2 Cancer Research
Q1 Oncology
14.
Rebenku, I., Lloyd, C. B., Szöllősi, J., Vereb, G.: Pixel-by-pixel autofluorescence corrected FRET in fluorescence microscopy improves accuracy for samples with spatially varied autofluorescence to signal ratio.
Sci. Rep. 13 (1), 1-15, (article identifier: 2934), 2023.
doi DEA WoS Scopus
Journal metrics:
D1 Multidisciplinary
15.
Rebenku, I., Bartha, F., Katona, T., Zsebik, B., Antalffy, G., Takács, L., Molnár, B., Vereb, G.: Taking molecular pathology to the next level: whole slide multicolor confocal imaging with the Pannoramic Confocal digital pathology scanner.
Cytom. Part A. 103 (3), 198-207, 2023.
doi DEA WoS Scopus
Journal metrics:
Q2 Cell Biology
Q1 Histology
Q1 Pathology and Forensic Medicine
2022
16.
Cserepes, M., Nelhűbel, G. A., Meilinger-Dobra, M., Herczeg, A., Türk, D., Hegedűs, Z., Svajda, L., Rásó, E., Ladányi, A., Csikó, K. G., Kenessey, I., Szöőr, Á., Vereb, G., Remenár, É., Tóvári, J.: EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.
Cancers (Basel). 14 (10), 1-15, (article identifier: 2407), 2022.
doi DEA WoS Scopus
Journal metrics:
Q2 Cancer Research
Q1 Oncology
17.
Blokon-Kogan, D., Levi-Mann, M., Malka-Levy, L., Itzhaki, O., Besser, M. J., Shiftan, Y., Szöőr, Á., Vereb, G., Gross, G., Abken, H., Weinstein-Marom, H.: Membrane anchored IL-18 linked to constitutively active TLR4 and CD40 improves human T cell antitumor capacities for adoptive cell therapy.
J Immunother Cancer. 10 (9), 1-12, (article identifier: 001544), 2022.
doi DEA WoS Scopus
Journal metrics:
D1 Cancer Research
D1 Immunology
D1 Immunology and Allergy
D1 Molecular Medicine
D1 Oncology
D1 Pharmacology
18.
Guti, E., Regdon, Z., Sturniolo, I., Kiss, A., Kovács, K., Demény, M. Á., Szöőr, Á., Vereb, G., Szöllősi, J., Hegedűs, C., Polgár, Z., Virág, L.: The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC.
Cancer Immunol. Immunother. 71 (9), 2151-2168, 2022.
doi DEA WoS Scopus
Journal metrics:
Q1 Cancer Research
Q1 Immunology
Q1 Immunology and Allergy
D1 Medicine (miscellaneous)
Q1 Oncology
19.
Pócsi, I., Máthéné Szigeti, Z., Emri, T., Boczonádi, I., Vereb, G., Szöllősi, J.: Use of red, far-red, and near-infrared light in imaging of yeasts and filamentous fungi.
Appl. Microbiol. Biotechnol. 106 (11), 3895-3912, 2022.
doi DEA WoS Scopus
Journal metrics:
Q1 Applied Microbiology and Biotechnology
Q1 Biotechnology
Q1 Medicine (miscellaneous)
2021
20.
Angyal, Á., Pénzes, Z., Alimohammadi, S., Horváth, D., Takács, L., Vereb, G., Zsebik, B., Bíró, T., Tóth, K. F., Lisztes, E., Tóth, I. B., Oláh, A., Szöllősi, A. G.: Anandamide Concentration-Dependently Modulates Toll-Like Receptor 3 Agonism or UVB-Induced Inflammatory Response of Human Corneal Epithelial Cells.
Int. J. Mol. Sci. 22 (15), 7776, (article identifier: 7776), 2021.
doi DEA WoS Scopus
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
Q1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
Q1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
21.
Mezősi-Csaplár, M., Szöllősi, J., Gottschalk, S., Vereb, G., Szöőr, Á.: Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models.
Cancers (Basel). 13 (17), 1-19, (article identifier: 4301), 2021.
doi DEA WoS Scopus
Journal metrics:
Q2 Cancer Research
Q1 Oncology
22.
Szöőr, Á., Szöllősi, J., Vereb, G.: From antibodies to living drugs: quo vadis cancer immunotherapy?.
Biol. Futura. 72 (1), 85-99, 2021.
doi DEA
Journal metrics:
Q2 Agricultural and Biological Sciences (miscellaneous)
Q3 Biochemistry, Genetics and Molecular Biology (miscellaneous)
23.
Potor, L., Hendrik, Z., Patsalos, A., Katona, É., Méhes, G., Póliska, S., Csősz, É., Kalló, G., Komáromi, I., Combi, Z., Posta, N., Sikura, K. É., Pethő, D., Oros, M., Vereb, G., Tóth, C., Gergely, P., Nagy, L., Balla, G., Balla, J.: Oxidation of hemoglobin drives a proatherogenic polarization of macrophages in human atherosclerosis.
Antioxid. Redox Signal. 35 (12), 917-950, 2021.
doi DEA WoS Scopus
Journal metrics:
D1 Biochemistry
Q1 Cell Biology
D1 Clinical Biochemistry
D1 Medicine (miscellaneous)
Q1 Molecular Biology
D1 Physiology
2020
24.
Tóth, G., Szöllősi, J., Abken, H., Vereb, G., Szöőr, Á.: A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts.
Int. J. Mol. Sci. 21 (3), 1-11, (article identifier: 1039), 2020.
doi DEA WoS Scopus
Journal metrics:
Q2 Catalysis
D1 Computer Science Applications
D1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
D1 Organic Chemistry
D1 Physical and Theoretical Chemistry
D1 Spectroscopy
25.
Volpin, V., Michels, T., Sorrentino, A., Menevse, A. N., Knoll, G., Ditz, M., Milenkovic, V. M., Chen, C. Y., Rathinasamy, A., Griewank, K., Boutros, M., Haferkamp, S., Berneburg, M., Wetzel, C. H., Seckinger, A., Hose, D., Goldschmidt, H., Ehrenschwender, M., Witzens-Harig, M., Szöőr, Á., Vereb, G., Khandelwal, N., Beckhove, P.: CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 Treatment.
Cancer Immunol. Res. 8, 1163-1179, 2020.
doi DEA WoS Scopus
Journal metrics:
D1 Cancer Research
D1 Immunology
DEENK University of Debrecen
© 2012 University of Debrecen
We use cookies on this site to enhance your user experience. By continuing to use the site, you agree to the use of cookies.